FDA Oncology Advisory Committee Is Still Pazdur’s Center of Excellence
Executive Summary
Richard Pazdur is moving to a new role in FDA as part of a reorganization driven by the Cancer 'Moonshot.' The most recent Oncologic Drugs Advisory Committee meeting, however, demonstrates that he is still very much in command of cancer drug reviews.
You may also be interested in...
US FDA’s ODAC: The Advisory Committee That Can Only Say ‘No’
It has been more than two years since a sponsor went before the Oncologic Drugs Advisory Committee and won a favorable vote on approval of a new drug application. Can FDA really expect an advisory committee to keep saying ‘no’ all the time?
FDA's Pazdur To Retain Drug Approval Duties In Oncology Center Of Excellence
Center for Drug Evaluation and Research's long-time director of oncology/hematology products office will continue as signatory on drug reviews even after new Cancer Moonshot-driven structure takes effect.
Spectrum's Apaziquone Pooled Analysis Can't Make Up For Negative Studies
Faced with two unsuccessful pivotal trials, FDA advisory committee concludes substantial evidence of a treatment effect in non-muscle invasive bladder cancer has not been demonstrated.